Abstract
No public abstract is available from the verified source records.
Contact and support
Need help, have a question, or want to contact the ResearchHub team?
© 2026 ResearchHub. Built for responsible scholarly connection.
Privacy-aware community infrastructureMonica Mehta
Abstract
Authors
Institutions
No ROR-resolved institution is linked to this work yet.
Provenance
crossref
Confidence 100%
datacite
Confidence 0%
No local reference links have been materialized yet.
No local citing links have been materialized yet.
Executive summary of the meeting of the 2018 ASHP Commission on Goals: Focus on Opioids
10.2146/ajhp180672 · 2019
Executive summary of the 2019 ASHP Commission on Goals: impact of artificial intelligence on healthcare and pharmacy practice
10.1093/ajhp/zxz205 · 2019
Executive summary of the meeting of the 2020 ASHP Commission on Goals: preparing the healthcare workforce for a digital future
10.1093/ajhp/zxaa395 · 2021
Executive summary of the meeting of the 2021 ASHP Commission on Goals: Optimizing Medication Outcomes Through Telehealth
10.1093/ajhp/zxac034 · 2022
Executive summary of the meeting of the 2022 ASHP Commission on Goals: Optimizing Hospital at Home and Healthcare Transformation
10.1093/ajhp/zxac216 · 2022
Executive summary of the meeting of the 2023 ASHP Commission on Goals: Optimizing Medication Therapy Through Advanced Analytics and Data-Driven Healthcare
10.1093/ajhp/zxad261 · 2024
Executive summary of the 2024 ASHP Commission on Goals: primary care delivery transformation
10.1093/ajhp/zxae324 · 2024
Executive summary of the 2025 ASHP Commission on Goals: Preparing for the Evolving Healthcare Landscape
10.1093/ajhp/zxaf309 · 2026
The landscape of cell and gene therapy today
10.1016/j.ymthe.2025.05.006 · 2025
Therapeutic in vivo genome editing: innovations and challenges in rAAV vector-based CRISPR delivery
10.1038/s41434-025-00573-2 · 2026
Chimeric antigen receptor therapy
10.1056/nejmra1706169 · 2018
Pharmacy Futures: Summit on Advanced Therapeutics
10.1093/ajhp/zxaf310 · 2026
Unresolved referenced work
2025
From vision to viability: developing infrastructure for cell and gene therapy programs
10.1016/j.jtct.2026.01.002
Noncanonical and mortality-defining toxicities of CAR T cell therapy
10.1038/s41591-025-03813-5 · 2025
Treatment-related adverse events of chimeric antigen receptor-T therapies for cancers in clinical trials: a systematic review and meta-analysis
10.1016/j.eclinm.2025.103267
Filling the gap: the workforce of tomorrow for CGT manufacturing as the sector advances
10.1016/j.jcyt.2024.03.007 · 2024
Virtual nursing and the future of workforce sustainability
10.1001/jamanetworkopen.2025.45603
Pharmacy-directed coordination of gene and high-cost therapies
10.1093/ajhp/zxaf119 · 2026
Unresolved referenced work
Kept as external metadata until matched
Unresolved referenced work
Kept as external metadata until matched
Unresolved referenced work
Kept as external metadata until matched
The Cell and Gene Therapy Access Model
10.1001/jama.2025.16537 · 2025
Gene therapy for sickle cell disease: practice recommendations from the American Society for Transplantation and Cellular Therapy and the International Society for Cell & Gene Therapy
10.1016/j.jtct.2026.03.007 · 2026
Unresolved referenced work
Kept as external metadata until matched
Transition from pediatric to adult care in sickle cell disease: establishing evidence-based practice and directions for research
10.1002/ajh.21880 · 2011
Balancing safety and innovation for cell-based regenerative medicine
10.1056/nejmsr1715626 · 2018
Unresolved referenced work
Kept as external metadata until matched
Unresolved referenced work
Kept as external metadata until matched
Unresolved referenced work
Kept as external metadata until matched
Cost-effectiveness of direct-acting antivirals for chronic hepatitis C virus in the United States from a payer perspective
10.18553/jmcp.2022.28.10.1138 · 2022
Point-of-care CAR T manufacturing solutions: can 1 model fit all?
10.1182/bloodadvances.2024012982 · 2024
Point-of-care CAR T manufacturing solutions: can 1 model fit all?
10.1182/bloodadvances.2024012982 · doi-reference
Cost-effectiveness of direct-acting antivirals for chronic hepatitis C virus in the United States from a payer perspective
10.18553/jmcp.2022.28.10.1138 · doi-reference
Balancing safety and innovation for cell-based regenerative medicine
10.1056/nejmsr1715626 · doi-reference
Transition from pediatric to adult care in sickle cell disease: establishing evidence-based practice and directions for research
10.1002/ajh.21880 · doi-reference
Gene therapy for sickle cell disease: practice recommendations from the American Society for Transplantation and Cellular Therapy and the International Society for Cell & Gene Therapy
10.1016/j.jtct.2026.03.007 · doi-reference
The Cell and Gene Therapy Access Model
10.1001/jama.2025.16537 · doi-reference
Pharmacy-directed coordination of gene and high-cost therapies
10.1093/ajhp/zxaf119 · doi-reference
Virtual nursing and the future of workforce sustainability
10.1001/jamanetworkopen.2025.45603 · doi-reference
Filling the gap: the workforce of tomorrow for CGT manufacturing as the sector advances
10.1016/j.jcyt.2024.03.007 · doi-reference
Treatment-related adverse events of chimeric antigen receptor-T therapies for cancers in clinical trials: a systematic review and meta-analysis
10.1016/j.eclinm.2025.103267 · doi-reference
Noncanonical and mortality-defining toxicities of CAR T cell therapy
10.1038/s41591-025-03813-5 · doi-reference
From vision to viability: developing infrastructure for cell and gene therapy programs
10.1016/j.jtct.2026.01.002 · doi-reference
Pharmacy Futures: Summit on Advanced Therapeutics
10.1093/ajhp/zxaf310 · doi-reference
Chimeric antigen receptor therapy
10.1056/nejmra1706169 · doi-reference
Therapeutic in vivo genome editing: innovations and challenges in rAAV vector-based CRISPR delivery
10.1038/s41434-025-00573-2 · doi-reference
The landscape of cell and gene therapy today
10.1016/j.ymthe.2025.05.006 · doi-reference
Executive summary of the 2025 ASHP Commission on Goals: Preparing for the Evolving Healthcare Landscape
10.1093/ajhp/zxaf309 · doi-reference
Executive summary of the 2024 ASHP Commission on Goals: primary care delivery transformation
10.1093/ajhp/zxae324 · doi-reference
Executive summary of the meeting of the 2023 ASHP Commission on Goals: Optimizing Medication Therapy Through Advanced Analytics and Data-Driven Healthcare
10.1093/ajhp/zxad261 · doi-reference
Executive summary of the meeting of the 2022 ASHP Commission on Goals: Optimizing Hospital at Home and Healthcare Transformation
10.1093/ajhp/zxac216 · doi-reference
Executive summary of the meeting of the 2021 ASHP Commission on Goals: Optimizing Medication Outcomes Through Telehealth
10.1093/ajhp/zxac034 · doi-reference
Executive summary of the meeting of the 2020 ASHP Commission on Goals: preparing the healthcare workforce for a digital future
10.1093/ajhp/zxaa395 · doi-reference
Executive summary of the 2019 ASHP Commission on Goals: impact of artificial intelligence on healthcare and pharmacy practice
10.1093/ajhp/zxz205 · doi-reference
Executive summary of the meeting of the 2018 ASHP Commission on Goals: Focus on Opioids
10.2146/ajhp180672 · doi-reference